CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)
The Phase I Efficacy and Safety Clinical Study of CD19/CD22-Dual-STAR-T Cells in Relapsed and Refractory B-ALL.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Hebei
-
Sanhe, Hebei, China, 065200
- Hebei Yanda Ludaopei Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ages 1 to 70 years.
Prelapsed and refractorys B-ALL at least with one of the following conditions:
- Could not achieve CR after 2course of chemotherapy.
- Could not achieve CR or relapse after first-line or multi-line salvage chemotherapy, or MRD≥0.1%.
- Relapse within 12 months after first remission or MRD≥0.1%.
- Relapse after achieved CR in allogeneic hematopoietic stem cell transplantation (HSCT), or MRD≥0.1%.
- For Ph + patients: Failure to tolerate TKI or TKI treatment failure could be enrolled.
- CD19 and/or CD22 positive within 3 months.
- ECOG 0-2.
- Estimated life expectancy ≥ 3 months.
- Women of childbearing age must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 12 months after discontinuation of treatment during the study period not pregnant inside.
- Patients who voluntarily sign informed consent and are willing to comply with treatment plans, visit arrangements, laboratory tests and other research procedures.
Exclusion Criteria:
- Active infections that are difficult to control
- HBV-DNA HCV-RNA and HIV ,either of which is positive
- Central nervous system leukemias that is symptomatic or uncontrolled by systemic chemotherapy and intrathecal chemotherapy
- Patients are receiving anti-GVHD treatment within 4 weeks of before screening.
- Performed major surgery within 4 weeks before screening.
- Patients have received chemotherapy within 7 days of screening.
- Experimental drugs were used within 4 weeks before screening.
- Received allogeneic cell therapy within 6 weeks prior to cell infusion.
- Patients have history of epilepsy or central nervous system diseases.
- Severe thyroid dysfunction
- Patients with active autoimmune disease.
- Pregnant or lactating women.
- The patient does not agree to use effective contraception during treatment and for the following 12 months;
- The researchers found that it was unsuitable for the recipients to be enrolled.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CD19/CD22-Dual-STAR-T
CD19/CD22-Dual-STAR-T cells are prepared via lentiviral infection.
5 days prior to infusion of Dual-STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 500mg/m2 for 3 days and take a rest for 2 days before infusion.
Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
|
Patients with B cell acute leukemia will be enrolled, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD22-Dual-STAR-T cells.Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of participants with adverse events.
Time Frame: 12 months
|
Percentage of participants with adverse events.
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Remission Rate(ORR)
Time Frame: 12 months
|
The percentage of participants who achieved complete remission(CR) and CR in over all participants.
|
12 months
|
|
Proliferation ratio of Dual-STAR-T cells
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Xian Zhang, PhD, Hebei Yanda Ludaopei Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HXYT-011
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.